Isis Pharmaceuticals Inc., of Carlsbad, Calif., said it started a phase I/II study of ISIS-DMPKRx in patients with myotonic dystrophy type 1, a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells.